Event Details
July 24, 2015
Description
Investor Relations Conference Call on Praluent hosted by Sanofi and Regeneron
Participants (3)
| Name | Type | Mentions | |
|---|---|---|---|
| Financial Community | person | 0 | View Entity |
| Regeneron | organization | 22 | View Entity |
| Sanofi | organization | 26 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_025891.jpg
This document is a press release or investor relations update from Sanofi and Regeneron dated around July 2015, detailing clinical trial results, pricing, and regulatory milestones for the cholesterol drug Praluent. It announces a positive opinion from the European Medicine Agency and schedules an investor conference call for July 24, 2015. The document bears a 'HOUSE_OVERSIGHT' footer, suggesting it was part of a document production to Congress, likely related to pharmaceutical pricing or regulatory investigations, though it contains no direct mentions of Jeffrey Epstein or his associates in this specific page.
Related Events
Events with shared participants
Investor Relations Conference Call hosted by Sanofi and Regeneron to discuss Praluent.
2015-07-24 • Teleconference / Webcast
Investor Relations Conference Call on Praluent for the financial community.
2015-07-24 • Teleconference / Webcast
Trading of Regeneron shares was halted pending news.
Date unknown
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Date unknown
ODYSSEY clinical trial program.
2025-12-01
Expected final decision by European Commission on Marketing Authorization Application
2015-09-01 • European Union
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event